期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 18, 期 4, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2022.2079322
关键词
RSV all infants; respiratory syncytial virus; RSV; RSV epidemiology; RSV paediatric burden; RSV prevention; LRTI; RSV vaccines; monoclonal antibodies
RSV is a highly contagious virus that is the leading cause of respiratory infections in children, resulting in a significant number of hospitalizations and deaths. Current preventive measures are not sufficient to meet the needs of all children, but new technologies under development offer hope for addressing this issue.
Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children <5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclonal antibodies to provide rapid long-lasting protection, and pediatric vaccines. RSV has been identified as a major global priority but a solution to tackle this unmet need for all children has yet to be implemented. New technologies represent the avenue for effectively addressing the leading-cause of hospitalization in children <1 years old.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据